These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 11428055)

  • 1. [Resistance to nucleoside reverse transcriptase inhibitors].
    Leal M; Santamaría JM
    Enferm Infecc Microbiol Clin; 2001 Feb; 19(Monografico):26-9. PubMed ID: 11428055
    [No Abstract]   [Full Text] [Related]  

  • 2. [Resistance to non-nucleoside reverse transcriptase inhibitors].
    Casado JL; López JC; Viciana P
    Enferm Infecc Microbiol Clin; 2001 Feb; 19(Monografico):30-3. PubMed ID: 11428057
    [No Abstract]   [Full Text] [Related]  

  • 3. [Human immunodeficiency virus and antiretroviral therapy resistance].
    Quirós E; Torti C; Carosi G
    Enferm Infecc Microbiol Clin; 2000 May; 18(5):234-7. PubMed ID: 10974768
    [No Abstract]   [Full Text] [Related]  

  • 4. Viral resistance: a major challenge in managing HIV disease.
    Boucher CA; Reedijk M
    J Biol Regul Homeost Agents; 1995; 9(3):91-4. PubMed ID: 8782014
    [No Abstract]   [Full Text] [Related]  

  • 5. [Drug clinics. How I treat HIV infections. II. Nucleoside reverse transcriptase inhibitors].
    Moutschen M; Nkoghe D; Léonard P; Demonty J
    Rev Med Liege; 1997 Dec; 52(12):750-2. PubMed ID: 9481171
    [No Abstract]   [Full Text] [Related]  

  • 6. Non-nucleoside HIV-1 reverse transcriptase inhibitors di-halo-indolyl aryl sulfones achieve tight binding to drug-resistant mutants by targeting the enzyme-substrate complex.
    Samuele A; Kataropoulou A; Viola M; Zanoli S; La Regina G; Piscitelli F; Silvestri R; Maga G
    Antiviral Res; 2009 Jan; 81(1):47-55. PubMed ID: 18984007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV resistance testing proves its value.
    Proj Inf Perspect; 1999 Sep; (28):14. PubMed ID: 11367356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence of dual sexual transmission of multi-resistant HIV with two years persistence of resistance to NRTI and NNRTI: a case report.
    Zaccarelli M; Marconi P; Visco-Comandini U; Liuzzi G; Sette P; Acinapura R; Mosti S; Ammassari A; Perno CF; Antinori A
    Infection; 2008 Mar; 36(2):178-80. PubMed ID: 17962906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors.
    Ghosn J; Chaix ML; Delaugerre C
    AIDS Rev; 2009; 11(3):165-73. PubMed ID: 19654858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experts discuss findings on drug resistance.
    Mellors J; Kemp S
    AIDS Alert; 2001 Aug; 16(8):103-4. PubMed ID: 11547700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Current situation of nucleoside reverse transcriptase inhibitors].
    Ngo Van P
    Ann Med Interne (Paris); 2000 Jun; 151(4):255-9. PubMed ID: 10922952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current insights into reverse transcriptase inhibitor-associated resistance.
    Wainberg MA; White AJ
    Antivir Ther; 2001; 6 Suppl 2():11-9. PubMed ID: 11678474
    [No Abstract]   [Full Text] [Related]  

  • 13. Slow-, tight-binding HIV-1 reverse transcriptase non-nucleoside inhibitors highly active against drug-resistant mutants.
    Cancio R; Mai A; Rotili D; Artico M; Sbardella G; Clotet-Codina I; Esté JA; Crespan E; Zanoli S; Hübscher U; Spadari S; Maga G
    ChemMedChem; 2007 Apr; 2(4):445-8. PubMed ID: 17323401
    [No Abstract]   [Full Text] [Related]  

  • 14. Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir.
    de Mendoza C; Jiménez-Nacher I; Garrido C; Barreiro P; Poveda E; Corral A; Zahonero N; González-Lahoz J; Soriano V
    Clin Infect Dis; 2008 Jun; 46(11):1782-5. PubMed ID: 18426370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding the basis of resistance in the irksome Lys103Asn HIV-1 reverse transcriptase mutant through targeted molecular dynamics simulations.
    Rodríguez-Barrios F; Gago F
    J Am Chem Soc; 2004 Dec; 126(47):15386-7. PubMed ID: 15563158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New trends in HIV].
    Volkert R
    Dtsch Med Wochenschr; 1998 Sep; 123(38):A7. PubMed ID: 9787287
    [No Abstract]   [Full Text] [Related]  

  • 17. Nucleoside reverse transcriptase inhibitor resistance mutations in subtype F1 strains isolated from heavily treated adolescents in Romania.
    Paraschiv S; Otelea D; Baicus C; Tinischi M; Costache M; Neaga E
    Int J Infect Dis; 2009 Jan; 13(1):81-9. PubMed ID: 18632295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors.
    Domaoal RA; Demeter LM
    Int J Biochem Cell Biol; 2004 Sep; 36(9):1735-51. PubMed ID: 15183341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experience with non-nucleoside reverse transcriptase inhibitors.
    Miller V; Staszewski S; Boucher CA; Phair JP
    AIDS; 1997; 11 Suppl A():S157-64. PubMed ID: 9451980
    [No Abstract]   [Full Text] [Related]  

  • 20. The effect of NNRTIs on HIV reverse transcriptase dimerization.
    Tachedjian G; Goff SP
    Curr Opin Investig Drugs; 2003 Aug; 4(8):966-73. PubMed ID: 14508881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.